Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Unaudited)

v2.4.0.6
Condensed Consolidated Balance Sheets (Unaudited) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Dec. 31, 2011
Current assets:    
Cash and cash equivalents $ 8,307 $ 5,882
Marketable securities 58,228 14,408
Collaboration receivable 16,412  
Prepaid expenses and other current assets 1,652 254
Total current assets 84,599 20,544
Property and equipment, net 684 543
Restricted cash and other assets 1,059 1,349
Total assets 86,342 22,436
Current liabilities:    
Accounts payable 995 2,389
Accrued clinical and development expenses 3,801 4,465
Accrued liabilities 1,437 1,737
Deferred revenue, current 7,188  
Total current liabilities 13,421 8,591
Warrant liability 75,759 9,209
Deferred revenue, non-current 48,263  
Deferred rent 273 153
Total liabilities 137,716 17,953
Commitments and contingencies (Note 7)      
Stockholders' equity (net capital deficiency):    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding      
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 55,122,594 shares at June 30, 2012 and 49,128,475 shares at December 31, 2011 55 49
Additional paid-in capital 299,244 256,563
Accumulated other comprehensive gain (loss) (13) (1)
Accumulated deficit (350,660) (252,128)
Total stockholders' equity (net capital deficiency) (51,374) 4,483
Total liabilities and stockholders' equity (net capital deficiency) $ 86,342 $ 22,436